Jiangsu Aidea Pharmaceutical announced that the company has completed the acquisition of 31.161% equity of Nandu Pharmaceuticals held by Huaxi Silver Peak, Hunan Kecheng, Xu Zhihuai, Chen Lei, and Yao Fandi by paying cash, with a transaction price of 0.15 billion yuan. Nandu Pharmaceuticals is mainly engaged in the research and development, production, and sales of biochemical pharmaceutical active pharmaceutical ingredients and formulations. Its main products include injection urokinase formulations and low molecular weight heparin sodium active pharmaceutical ingredients. This transaction does not constitute a related party transaction and does not constitute a restructuring for listing.